drugset / Trial / NCT03020004
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir (ASC08) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.
Timeline
- Start
- 2016-01
- Primary completion
- 2016-11
- Completion
- 2017-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | danoprevir | Small molecule | 100 mg | Oral |
| Background | PegIFN subcutaneous injection at 180 mcg weekly | Unknown | 180 ug | Subcutaneous |
| Background | Ribavirin | Small molecule | 1000 mg | Oral |
| Background | Ribavirin | Small molecule | 1200 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |